专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012033720A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID 审中-公开
标题翻译：用于减少尿酸的苯甲酸化合物
公开(公告)号：WO2012033720A1
公开(公告)日：2012-03-15
申请号：PCT/US2011/050475
申请日：2011-09-06
申请人： WELLSTAT THERAPEUTICS CORPORATION , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K31/19
CPC分类号： A61K31/192 , A61K45/06 , C07C65/24 , C07C205/59
摘要： Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I). The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium Jalciparum-induced inflammation. In Formula I, t, q, r, R6, R7, X and A are as defined herein.
摘要翻译：减少哺乳动物受试者的尿酸，并通过施用式（I）的化合物来增加尿酸的排泄。本发明化合物的尿酸降低作用用于治疗或预防多种病症，包括痛风，高尿酸血症，升高的尿酸水平，不符合常规诊断为高尿酸血症，肾功能不全，肾结石的水平心血管疾病，发展心血管疾病的风险，肿瘤溶解综合征，认知障碍，早发性原发性高血压和恶性疟原虫诱发的炎症。在式I中，t，q，r，R6，R7，X和A如本文所定义。

2. 发明申请

WO2007137008A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007137008A3
公开(公告)日：2008-08-28
申请号：PCT/US2007068745
申请日：2007-05-11
申请人： WELLSTAT THERAPEUTICS CORP , SHARMA SHALINI , VON BORSTEL REID W
发明人： SHARMA SHALINI , VON BORSTEL REID W
IPC分类号： A61K31/19 , A61K31/34 , C07C229/00
CPC分类号： C07D317/32 , C07C59/68
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R 3 and R 4 together are alkyl having two or three carbon atoms; or R 3 and R 4 are the same as each other and each is methyl or ethyl; R 5 is hydrogen or alkyl having from one to six carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or A is cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了用于治疗各种代谢紊乱（例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化）的药剂，其中n为1 或2; m为0,1,2,3,4,5,6,7或8; q为0或1; t为0或1; R 1是具有1至3个碳原子的烷基; R 2是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; R 3和R 4一起是具有两个或三个碳原子的烷基; 或R 3和R 4彼此相同，各自为甲基或乙基; R 5是氢或具有1至6个碳原子的烷基。 A是未取代的或被1或2个选自：卤素，羟基，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或A是具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或A是具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合。或者，试剂可以是式（I）化合物的药学上可接受的盐。

3. 发明申请

WO2007095462A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007095462A3
公开(公告)日：2008-05-02
申请号：PCT/US2007061908
申请日：2007-02-09
申请人： WELLSTAT THERAPEUTICS CORP , SHARMA SHALINI , VON BORSTEL REID W
发明人： SHARMA SHALINI , VON BORSTEL REID W
IPC分类号： A61K31/055 , C07C39/21 , C07C39/27 , C07C59/01
CPC分类号： C07C43/23
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, hydroxy, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of formula (I).
摘要翻译：公开了可用于治疗各种代谢紊乱（例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化）的药剂。式（I）其中n为1或2; q为0或1; t为0或1; R 1是具有1至3个碳原子的烷基; R 2是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代的或被1或2个选自：卤素，具有1或2个碳原子的烷基，全氟甲基，羟基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或具有3至6个环碳原子的环烷基，其中所述环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合。或者，该试剂可以是式（I）化合物的药学上可接受的盐。

4. 发明申请

WO2007101060A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007101060A3
公开(公告)日：2007-12-13
申请号：PCT/US2007062574
申请日：2007-02-22
申请人： WELLSTAT THERAPEUTICS CORP , SHARMA SHALINI , VON BORSTEL REID W
发明人： SHARMA SHALINI , VON BORSTEL REID W
IPC分类号： A01N31/14 , A61K31/075
CPC分类号： C07D263/14
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R and R is hydrogen or hydroxy and the other is hydrogen; or R 3 and R 4 together are =0. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了用于治疗各种代谢疾病的药剂，例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化症，其中n是1或2; m是0,1,2,3或4; q是0或1; t是0或1; R 1是具有1至3个碳原子的烷基; R 2为氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; R和R之一是氢或羟基，另一个是氢; 或者R 3和R 4一起是= 0。 A是未取代的或被1或2个选自以下的基团取代的苯基：卤素，羟基，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基; 或具有3至6个环碳原子的环烷基，其中所述环烷基未被取代或者一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳族环，并且所述杂芳族环通过环碳与式I化合物的其余部分共价结合。或者，所述药剂可以是式（I）化合物的药学上可接受的盐。

5. 发明申请

WO2007087504A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007087504A3
公开(公告)日：2007-11-15
申请号：PCT/US2007060830
申请日：2007-01-22
申请人： WELLSTAT THERAPEUTICS CORP , SHARMA SHALINI , VON BORSTEL REID W
发明人： SHARMA SHALINI , VON BORSTEL REID W
IPC分类号： A01N35/00 , A61K31/12
CPC分类号： C07D307/33
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of formula (I).
摘要翻译：公开了用于治疗各种代谢疾病如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化的药物，其中n是1或2; m是0,1,2,3或4; q是0或1; t是0或1; R 1是具有1至3个碳原子的烷基; R 2为氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; A是未取代的或被1或2个选自以下的基团取代的苯基：卤素，羟基，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基; 或具有3至6个环碳原子的环烷基，其中所述环烷基未被取代或者一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳族环，并且杂芳族环通过环碳与式（I）化合物的其余部分共价结合。或者，该药剂可以是式（I）化合物的药学上可接受的盐。

6. 发明申请

WO2006127133A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2006127133A2
公开(公告)日：2006-11-30
申请号：PCT/US2006/012050
申请日：2006-03-31
申请人： WELLSTAT THERAPEUTICS CORPORATION , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K31/165
CPC分类号： C07C259/06 , C07C235/34
摘要： Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, 4 or 5; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R 3 is hydrogen or -(CH 2 ) g OH wherein g is 0, 1 or 2; R 4 is hydrogen, methyl or ethyl; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; or a pharmaceutically acceptable salt of the compound.
摘要翻译：公开了可用于治疗各种代谢紊乱（例如胰岛素抵抗综合征，糖尿病，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化）的化合物。其中n为1或2; m为0,1,2,3,4或5; q为0或1; t为0或1; R 1是具有1至3个碳原子的烷基; R 2是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; R 3是氢或 - （CH 2 CH 2）n OH其中g是0,1或2; R 4是氢，甲基或乙基; A是未取代的或被1或2个选自：卤素，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式I化合物的其余部分共价结合; 或该化合物的药学上可接受的盐。

7. 发明申请

WO2009158527A1 DRY SANITIZING PATCH FOR DECREASING HUMAN PATHOGEN TRANSMISSION 审中-公开
标题翻译：用于减少人类病原传播的干燥系统
公开(公告)号：WO2009158527A1
公开(公告)日：2009-12-30
申请号：PCT/US2009/048706
申请日：2009-06-25
申请人： FILLIGENT LIMITED , MOWBRAY-D'ARBELA, Melissa , MARWAH, Ranjan , STEWART, Neal, G. , LO, Lok, Yuen , LAU, Francis, Chi Nan , RYAN, Dacey, J. , VON BORSTEL, Reid, W.
发明人： MOWBRAY-D'ARBELA, Melissa , MARWAH, Ranjan , STEWART, Neal, G. , LO, Lok, Yuen , LAU, Francis, Chi Nan , RYAN, Dacey, J. , VON BORSTEL, Reid, W.
IPC分类号： C11D3/37
CPC分类号： A01N25/34 , A61K9/7084 , A61L2/26 , Y10T156/10 , A01N41/02 , A01N41/04 , A01N43/66 , A01N59/16 , A01N59/20 , A01N61/00
摘要： A dry sanitizing patch for use in decreasing the transmission of one or more than one human pathogen, the dry sanitizing patch comprising: a) a binding layer comprising a fabric comprising one or more than one binding substance comprising one or more than one human pathogen binding group for chemically attaching the human pathogen to the binding substance; b) an adhesive layer connected to the binding layer, and comprising an adhesive suitable for reversibly attaching the dry sanitizing patch to a surface; and c) a backing layer removably connected to the adhesive layer to protect the adhesive layer until the patch is ready for use.
摘要翻译：一种用于减少一种或多于一种人类病原体的传播的干燥消毒贴剂，所述干性消毒贴剂包括：a）包含一种或多种包含一种或多于一种人类病原体结合的结合物质的织物的结合层用于将人类病原体化学连接到结合物质的组; b）连接到粘合层的粘合剂层，并且包括适于可逆地将干消毒贴片附接到表面的粘合剂; 以及c）可剥离地连接到所述粘合剂层的背衬层，以保护所述粘合剂层，直到所述贴剂准备使用为止。

8. 发明申请

WO2007137008A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007137008A2
公开(公告)日：2007-11-29
申请号：PCT/US2007/068745
申请日：2007-05-11
申请人： WELLSTAT THERAPEUTICS CORPORATION , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： SHARMA, Shalini , VON BORSTEL, Reid, W.
IPC分类号： A61K31/195
CPC分类号： C07D317/32 , C07C59/68
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R 3 and R 4 together are alkyl having two or three carbon atoms; or R 3 and R 4 are the same as each other and each is methyl or ethyl; R 5 is hydrogen or alkyl having from one to six carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or A is cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了用于治疗各种代谢紊乱（例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化）的药剂，其中n为1 或2; m为0,1,2,3,4,5,6,7或8; q为0或1; t为0或1; R 1是具有1至3个碳原子的烷基; R 2是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; R 3和R 4一起是具有两个或三个碳原子的烷基; 或R 3和R 4彼此相同，各自为甲基或乙基; R 5是氢或具有1至6个碳原子的烷基。 A是未取代的或被1或2个选自：卤素，羟基，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或A是具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或A是具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合。或者，试剂可以是式（I）化合物的药学上可接受的盐。

9. 发明申请

WO2007121439A2 METHOD AND DEVICE FOR MAKING TOBACCO SMOKE FILTERS 审中-公开
标题翻译：制造烟草烟雾过滤器的方法和装置
公开(公告)号：WO2007121439A2
公开(公告)日：2007-10-25
申请号：PCT/US2007/066789
申请日：2007-04-17
申请人： FILLIGENT LIMITED , STEWART, Neal G. , MAKEPEACE, Robert D. , VON BORSTEL, Reid W.
发明人： STEWART, Neal G. , MAKEPEACE, Robert D. , VON BORSTEL, Reid W.
IPC分类号： A24D3/14
CPC分类号： A24D3/14 , A24D3/022 , A24D3/0287
摘要： A composition useful for treating the substrate of a tobacco smoke filter. A tobacco smoke filter comprising one or more than one free porphyrin or one or more than one free metal phthalocyanine. A seamless tobacco smoke filter (80, 90) comprising a first segment and a second segment. A device (110) for making a tobacco smoke filter from tobacco smoke filter substrate comprising a rod maker machine (112) and an applicator (120) for applying one or more than one additive intermittently to the substrate in a plurality of spaced bands.
摘要翻译：用于处理烟草烟雾过滤器的底物的组合物。一种烟草烟雾过滤器，其包含一种或多于一种的游离卟啉或一种或多于一种的游离金属酞菁。一种无烟烟草烟雾过滤器（80,90），包括第一段和第二段。一种用于从烟草烟雾过滤器基材制造烟草烟雾过滤器的装置（110），包括用于将多个间隔的带间歇地施加一个或多于一个添加剂的棒制造机（112）和施加器（120）。

10. 发明申请

WO2007101060A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译：用于治疗代谢性疾病的化合物
公开(公告)号：WO2007101060A2
公开(公告)日：2007-09-07
申请号：PCT/US2007/062574
申请日：2007-02-22
申请人： WELLSTAT THERAPEUTICS CORPORATION , SHARMA, Shalini , VON BORSTEL, Reid, W.
发明人： SHARMA, Shalini , VON BORSTEL, Reid, W.
CPC分类号： C07D263/14
摘要： Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R 1 is alkyl having from 1 to 3 carbon atoms; R 2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R and R is hydrogen or hydroxy and the other is hydrogen; or R 3 and R 4 together are =0. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).
摘要翻译：公开了可用于治疗各种代谢紊乱（例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化）的药剂，其中n为1或2; m为0,1,2,3或4; q为0或1; t为0或1; R 1是具有1至3个碳原子的烷基; R 2是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基; R和R中的一个是氢或羟基，另一个是氢; 或R 3和R 4一起= 0。 A是未取代的或被1或2个选自：卤素，羟基，具有1或2个碳原子的烷基，全氟甲基，具有1或2个碳原子的烷氧基和全氟甲氧基取代的苯基; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳独立地被甲基或乙基单取代; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式I化合物的其余部分共价结合。或者，试剂可以是式（I）化合物的药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式